Immunome, Inc.
IMNM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9 | $14 | $0 | $0 |
| % Growth | -35.5% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $9 | $14 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $130 | $23 | $23 | $14 |
| G&A Expenses | $33 | $20 | $14 | $11 |
| SG&A Expenses | $33 | $20 | $14 | $11 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $152 | $81 | $0 | $0 |
| Operating Expenses | $315 | $124 | $37 | $25 |
| Operating Income | -$306 | -$110 | -$37 | -$25 |
| % Margin | -3,382.4% | -781.4% | – | – |
| Other Income/Exp. Net | $13 | $3 | $0 | $0 |
| Pre-Tax Income | -$293 | -$107 | -$37 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$293 | -$107 | -$37 | -$25 |
| % Margin | -3,240.4% | -761.9% | – | – |
| EPS | -5 | -5.38 | -3.09 | -2.14 |
| % Growth | 7.1% | -74.1% | -44.4% | – |
| EPS Diluted | -5 | -5.38 | -3.09 | -2.14 |
| Weighted Avg Shares Out | 59 | 20 | 12 | 12 |
| Weighted Avg Shares Out Dil | 59 | 20 | 12 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $3 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | -$151 | -$28 | -$36 | -$24 |
| % Margin | -1,674.1% | -199.7% | – | – |